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Abstract
Background
Post-traumatic stress disorder (PTSD) is a severe and disabling condition that may lead to
functional impairment and reduced productivity. Psychological interventions have been
shown to be effective in its management. The objective of this study was to assess the cost-
effectiveness of a range of interventions for adults with PTSD.
Methods
A decision-analytic model was constructed to compare costs and quality-adjusted life-years
(QALYs) of 10 interventions and no treatment for adults with PTSD, from the perspective of
the National Health Service and personal social services in England. Effectiveness data
were derived from a systematic review and network meta-analysis. Other model input
parameters were based on published sources, supplemented by expert opinion.
Results
Eye movement desensitisation and reprocessing (EMDR) appeared to be the most cost-
effective intervention for adults with PTSD (with a probability of 0.34 amongst the 11 evalu-
ated options at a cost-effectiveness threshold of £20,000/QALY), followed by combined
somatic/cognitive therapies, self-help with support, psychoeducation, selective serotonin
reuptake inhibitors (SSRIs), trauma-focused cognitive behavioural therapy (TF-CBT), self-
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help without support, non-TF-CBT and combined TF-CBT/SSRIs. Counselling appeared to
be less cost-effective than no treatment. TF-CBT had the largest evidence base.
Conclusions
A number of interventions appear to be cost-effective for the management of PTSD in
adults. EMDR appears to be the most cost-effective amongst them. TF-CBT has the largest
evidence base. There remains a need for well-conducted studies that examine the long-
term clinical and cost-effectiveness of a range of treatments for adults with PTSD.
Introduction
A considerable proportion of people exposed to trauma, around 5.6%, will develop post-trau-
matic stress disorder (PTSD) [1]. PTSD is a severe and disabling condition that may lead to
functional impairment and reduced productivity [2]. A number of psychological interventions
have been shown to be effective in the treatment of PTSD in adults, predominantly eye move-
ment desensitisation and reprocessing (EMDR) and trauma-focused cognitive behavioural
therapy (TF-CBT) [3]. However, many people with PTSD delay seeking help or are not identi-
fied by health services [4]. Given the variety of available interventions and the need for efficient
use of healthcare resources, the objective of this study was to examine the cost-effectiveness of
a range of psychological interventions for the treatment of PTSD in adults from the perspective
of the National Health Service (NHS) and Personal Social Services (PSS) in England, using
decision-analytic economic modelling.
The analysis presented here is part of the work that informed the updating of national guid-
ance for the management of PTSD in England, published by the National Institute for Health
and Care Excellence (NICE) [5]. The guideline was developed by a guideline committee, an
independent multi-disciplinary group of clinical academics, health professionals and service
user and carer representatives with expertise and experience in the field of PTSD. The commit-
tee contributed to the development of the economic model by providing advice on issues relat-
ing to the natural history and treatment patterns of PTSD in the UK, and on model inputs in
areas where evidence was lacking.
Methods
Population
The study population comprised adults presenting in primary care with clinically important
post-traumatic stress symptoms, defined by a diagnosis of PTSD according to the Diagnostic
and Statistical Manual of Mental Disorders (DSM), the World Health Organization (WHO)
International Classification of Diseases (ICD) or similar criteria, or by clinically significant
PTSD symptoms, indicated by a PTSD symptom score above threshold on a validated scale,
that are present for more than 3 months after a traumatic event.
The starting age of the cohorts in the economic model was 39 years, to reflect the mean age
of adults with PTSD presenting to healthcare services in the UK [6]. The percentage of women
in each cohort at the start of the model was 51.6%, calculated using national statistics for the
general population [7], and data on the percentage of people screened positive for PTSD by
age and sex in England [4]. The starting age and gender mix of the cohorts was used to esti-
mate mortality risks and gender-specific quality-adjusted life-years (QALYs).
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Interventions
The interventions considered in the economic analysis were selected from those considered in
a network meta-analysis (NMA) of randomised controlled trials (RCTs) of psychological treat-
ments for adults with PTSD ([3]; see S2 Appendix for inclusion criteria for the NMA). We
included only interventions that had been tested on at least 100 individuals in the NMA of
changes in PTSD symptoms at treatment endpoint, as this was deemed the minimum adequate
evidence base that would enable robust conclusions to be drawn on clinical and cost-effective-
ness. Moreover, we included only interventions that had shown a higher mean effect in com-
parison with waitlist. Selective serotonin reuptake inhibitors (SSRIs) were included in the
analysis as they were relevant comparators to psychological interventions.
The economic analysis evaluated the following interventions:
• EMDR
• TF-CBT
• Non-TF-CBT
• Combined somatic/cognitive therapies
• SSRIs
• Combined TF-CBT/SSRIs
• Self-help with support
• Self-help without support
• Counselling
• Psychoeducation
• No treatment, reflected in waitlist RCT arms.
TF-CBT is a broad class of psychological interventions that predominantly use trauma-
focused cognitive, behavioural or cognitive-behavioural techniques and exposure approaches
to treatment. Although some interventions place their main emphasis on exposure and others
on cognitive techniques, most use a combination of both. TF-CBT includes therapies such as
cognitive therapy, cognitive processing therapy, exposure therapy/prolonged exposure, virtual
reality exposure therapy, mindfulness-based cognitive therapy and narrative exposure therapy.
Although the specific interventions that make up a class do not include exactly the same con-
tent or follow the same manual, they use the same broad approach and there is considerable
overlap in the proposed mechanisms. In the economic analysis that informed the NICE guide-
line [5] we divided the TF-CBT class by the number of sessions and format of delivery and cre-
ated separate categories of TF-CBT treatment according to their intensity, as these differences
in resource use comprised practical considerations that informed the guideline recommenda-
tions; in addition to different intervention costs, each TF-CBT category had its own clinical
effectiveness, estimated in the guideline NMAs. However, in the analyses we present here, we
considered TF-CBT as an umbrella term of interventions that share a similar approach to
treatment, in order to investigate the overall performance of the TF-CBT class relative to other
treatments, regardless of its mode of delivery. Resource use for TF-CBT in the economic analy-
sis we present here was determined by the average resource use reported in the TF-CBT trials
informing the analysis, considering also that their vast majority assessed individual forms of
TF-CBT.
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Non-TF-CBT is a class of interventions that focus on current symptoms of PTSD without
re-visiting the trauma experience. Combined somatic/cognitive therapies, such as emotional
freedom techniques and thought field therapy, are exposure-based therapies with both cogni-
tive and somatic components that utilise the tapping of points on the body [8, 9]. EMDR is
based on a theoretical model which posits that the dysfunctional intrusions, emotions and
physical sensations experienced by trauma victims are due to the improper storage of the trau-
matic event in implicit memory. The EMDR procedures are based on stimulating the patient’s
own information processing in order to help integrate the targeted event as an adaptive contex-
tualised memory [10]. Counselling is a type of psychological treatment that builds on the con-
cept of client-centred therapy by Rogers [11]. It has been described in the relevant literature as
non-directive counselling, supportive counselling, supportive psychotherapy, or person-cen-
tred counselling. Individuals are helped to focus on their thoughts, feelings and behaviour; to
reach clearer self-understanding; and to find and use their strengths so that they cope more
effectively with their lives by making appropriate decisions, or by taking relevant action. Coun-
selling is primarily non-directive and non-advisory, but recognises that some situations require
positive guidance by means of information and advice. Psychoeducation involves the provision
of information about the nature and causes of PTSD, and strategies and treatments that can
help address PTSD symptoms. It can be delivered individually, but is commonly delivered to
groups. Psychoeducation is usually non-directive and takes an educational didactic format.
Finally, self-help therapies include interventions such as internet-based TF-CBT or other com-
puterised psychological therapies, expressive writing and cognitive bibliotherapy. Self-help
with support includes interventions in which therapist’s input is an integral part of the inter-
vention; in self-help without support the therapist’s input is minimal or absent.
The guideline analysis included interventions tested on at least 50 people in the NMA of
changes in PTSD symptoms at treatment endpoint, whereas here we used a threshold of at
least 100 people to improve the robustness of the results. The impact of increasing this thresh-
old was the omission of interpersonal psychotherapy and present-centered therapy from the
analysis presented here; both interventions were shown to occupy middle-to-lower cost-effec-
tiveness rankings in the guideline analysis, and therefore their omission had no impact on the
overall conclusions of our analysis.
Economic model structure
A hybrid decision-analytic model consisting of a decision-tree followed by a three-state Mar-
kov model was constructed using Microsoft Office Excel 2013 to estimate total costs and
QALYs associated with each treatment. The model structure was determined by the natural
history of PTSD, its treatment patterns in the UK, and the availability of relevant clinical and
epidemiological data (Fig 1).
The model followed hypothetical cohorts of adults with PTSD, initiated on each of the treat-
ments assessed. The treatment duration for each of the assessed options equalled 3 months (12
weeks), according to the average duration of interventions in trials and routine clinical practice
(range 4–20 weeks). Following a course of treatment, people in each cohort either remitted
(entering a state of ‘no-PTSD’) or failed to remit, remaining in a ‘PTSD’ state. Those initiated
on SSRIs alone or in combination were given 3 months of maintenance pharmacological ther-
apy if they had remitted. Death was not considered during provision of interventions, as no
relevant differential mortality data are available. In the next 3 months of follow-up, those who
had remitted could remain in remission, relapse to PTSD or die. Those who had not remitted
could remain in the ‘PTSD’ state, remit (and move to ‘no-PTSD’) or die. The length of the
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follow-up period immediately post-treatment was set at 3 months as this is the period for
which most follow-up data are reported in RCTs of psychological interventions for PTSD.
After that point, people in each cohort entered the Markov model, run in 3-month cycles,
for consistency with the duration of the two periods of the decision-tree. In each cycle, they
remained in the same health state or moved between the states of ‘PTSD’ and ‘no-PTSD’ or
moved to death (absorbing state). People in both the ‘PTSD’ and the ‘no-PTSD’ states received
primary, community and secondary healthcare and personal social services, as relevant to their
health state. A half-cycle correction was applied.
The time horizon of the analysis was 3 years (36 months), comprising 6 months in the deci-
sion tree and 2.5 years (10 x 3-month cycles) in the Markov component of the model. This
time frame was deemed adequate to capture longer-term costs and effects of treatment, with-
out making significant extrapolations and assumptions over the course of PTSD.
Effectiveness data
We obtained effectiveness data from a systematic review and NMA of psychological treatments
for adults with PTSD [3]. We utilised the results of 2 NMAs of changes in PTSD symptoms:
between baseline and treatment endpoint; and between baseline and 1-4-month follow-up.
Details on the NMAs, including the studies and data that informed them, the selection of the
effectiveness data and the transformations required for use in the economic model are pro-
vided in S1 File.
The outputs of the NMA of changes in PTSD symptoms between baseline and treatment
endpoint informed the intervention effects in the model period of 0–3 months. For the 3–6
month follow-up period, the base-case economic analysis conservatively assumed that the
active intervention effects were not retained and equalled the effect of no treatment; this was
decided because the results of the NMA of changes in PTSD symptoms between baseline and
1-4-month follow-up were based on limited evidence and showed considerable uncertainty.
Nevertheless, data from this NMA were used in a secondary analysis, to inform effects for each
active intervention during 3–6 months after treatment initiation.
Fig 1. Schematic diagram of the economic model.
https://doi.org/10.1371/journal.pone.0232245.g001
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Baseline probability of remission
The probability of remission for no treatment (baseline) and for all model arms beyond treat-
ment endpoint (i.e. for all treatment options during 3–6 months after treatment initiation in
the base-case analysis and for all treatment options during 6–36 months after treatment initia-
tion in both the base-case and secondary analysis) was estimated using data from an Australian
national mental health survey [12]. We considered the survey participants to be representative
of our study population, which was adults presenting in primary care with symptoms of
PTSD. Details on the methods used for the estimation of the baseline probability of remission
are provided in S2 File.
Risk of relapse
Due to lack of published evidence, an annual risk of relapse of 0.10 was assumed across all
treatment arms, based on the committee’s expert opinion; this was translated into a 3-month
probability of relapse of 0.026 assuming an exponential function, which was applied in the
3-month follow-up period of the decision-tree and over the whole duration of the Markov
model. This assumption was tested in a sensitivity analysis.
Risk of development of side effects from SSRI treatment
The probability of developing common side effects from SSRIs (headaches, nausea or vomit-
ing, agitation, sedation and sexual dysfunction) was estimated from a retrospective analysis of
a large US managed care claims database on 40,017 people with depression who were initiated
on antidepressant monotherapy, including SSRIs [13]. Serious side effects from SSRIs (such as
death, attempted suicide or self-harm, falls, fractures, stroke, epilepsy/seizures) were not con-
sidered; however, their omission is not expected to have had a significant impact on the eco-
nomic results, due to their low incidence in the study population [14, 15].
Mortality
PTSD is associated with an increased risk of mortality. The hazard ratio of death associated
with PTSD, adjusted for confounders such as age, gender, diabetes mellitus and hypertension
was obtained from a study on 637 veterans in the US [16]. This ratio was applied onto general
mortality statistics for England [17] to estimate the annual mortality risk in people with PTSD
over the time period they experienced PTSD symptoms. People without PTSD symptoms had
the mortality risk of the general population.
Utility data
Utility scores express preferences for the health-related quality of life (HRQoL) in distinct
health states; they are necessary for the estimation of QALYs. Following a systematic literature
search of utility data for PTSD, the base-case economic analysis used utility scores generated
from HRQoL ratings of Australian adult participants in a national mental health survey, some
of whom had a diagnosis of PTSD according to DSM-4 criteria [18]. HRQoL was assessed with
the Assessment of Quality of Life measure (http://www.aqol.com.au). The study provided gen-
der-specific data for people with PTSD and people who were PTSD-free following evidence-
based treatment, which corresponded directly to the model health states of interest.
In a sensitivity analysis, we used utility data derived from a sample of 808 US veterans
attending primary care clinics, 97 of whom had developed PTSD, adjusted for confounders
such as gender, employment status, presence of disability, and mental and physical health
comorbidities [19]. HRQoL was assessed using SF-36, which was converted to utility scores
PLOS ONE Cost-effectiveness of psychological treatments for PTSD in adults
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using the UK algorithm [20]. Data from this study indicated a narrower utility benefit fol-
lowing remission from PTSD compared with the utility data used in the base-case analysis.
The mean utility decrement in people experiencing common side effects from SSRIs was
estimated using EQ-5D scores of participants in a US medical expenditure survey, some of
whom had depression and experienced side effects from antidepressant treatment [21]. This
utility decrement was applied only over the period that people received SSRI treatment.
Resource use and cost data
The analysis included intervention costs (healthcare professional time, drug acquisition and
equipment/infrastructure required for self-help interventions), costs of managing side effects
from medication, and costs relating to the ‘PTSD’ and ‘no-PTSD’ health states including costs
of primary, community and secondary healthcare and PSS costs.
Intervention costs (Table 1) were calculated by combining resource use reported in RCTs
included in the NMA that informed the economic analysis (i.e. number and duration of thera-
peutic sessions and mean daily dosage of sertraline, which was the most commonly used SSRI
in trials), modified to represent routine UK practice, with respective national unit costs. All
psychological interventions, with the exception of self-help and psychoeducation, were
assumed to be delivered in a primary care setting by Band 7 psychological therapists according
to the NHS Agenda for Change (AfC) pay-scales for community-based scientific and profes-
sional staff, to reflect routine practice in the UK. Psychoeducation was assumed to be delivered
by AfC band 5 Psychological Well-being Practitioners (PWPs) and self-help by AfC band 6
psychological therapists. People receiving SSRIs attended general practitioner (GP) monitor-
ing visits and undertook routine laboratory testing. Those experiencing side effects had one
extra GP contact every 3 months and received medication for their management. For self-help
therapies we included the cost of the provider of digital mental health programmes, and costs
of hardware and capital overheads.
Unit costs were estimated using a combination of data derived from national sources and
other published evidence [22–26]. Health professional unit costs included wages/salary, salary
on-costs, capital and other overheads, qualification costs where available, and supervision
costs. The ratio of direct (face-to-face) to indirect (preparation and administrative tasks) health
professionals’ time was taken into account. Details on the methods and sources used to esti-
mate therapists’ unit costs are reported in S3 File.
Annual costs associated with the PTSD and no-PTSD health states were estimated using
predominantly NHS and PSS usage data from a national psychiatric morbidity survey con-
ducted in England in 2014 [4], supplemented with resource use data from other published
sources [27–29] and expert opinion, which were subsequently combined with national unit
costs [22, 23, 30]. Costs for each state included inpatient hospital stays and outpatient visits,
contacts with GPs, psychiatrists, psychologists, social workers, community psychiatric and
learning disability nurses, other nursing services, self-help and support groups, home help or
home care, outreach or family support workers and community day-care centres. Details on
the methods and data used to estimate annual costs associated with the PTSD and no-PTSD
health states are provided in S4 File. These were then translated into 3-month cost figures that
informed the economic model. Because the estimated health state-related costs were based to a
large extent on expert opinion, a sensitivity analysis was conducted, in which PTSD costs were
varied by ±50%.
Costs were expressed in 2017 prices, uplifted, where necessary, using the Hospital and
Community Health Services Pay and Prices Index [22].
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Discounting
Costs and QALYs were discounted at 3.5% annually as recommended by NICE [31].
Analysis
To account for the uncertainty around input parameter point estimates, a probabilistic analysis
was undertaken, in which input parameters were assigned probabilistic distributions [32]. Sub-
sequently, 10,000 iterations were performed, each drawing random values out of the distribu-
tions fitted onto the model input parameters. Mean costs and QALYs for each treatment were
calculated by averaging across the 10,000 iterations. The Net Monetary Benefit (NMB) for
each intervention was estimated for each iteration and averaged across the 10,000 iterations,
determined by the formula
NMB ¼ E � l  C
where E and C are the effects (QALYs) and costs of each intervention, respectively, and ĕ rep-
resents the willingness-to-pay per unit of effectiveness, set at the NICE lower cost-effectiveness
threshold of £20,000/QALY [31]. The intervention with the highest NMB is the most cost-
effective option [33].
Table 1. Intervention costs of treatments for adults with PTSD (2017 prices).
Intervention Resource use details Intervention cost
EMDR 6 x 1.5 hr individual sessions (9 hours) delivered by a Band 7 psychological therapist £912
TF-CBT 9 x 1.5 hr individual sessions (13.5 hours) delivered by a Band 7 psychological therapist £1,368
non-TF-CBT 9 x 1 hr individual sessions (9 hours) delivered by a Band 7 psychological therapist £912
Combined somatic/cognitive
therapies
4 x 1 hr individual sessions (4 hours) delivered by a Band 7 psychological therapist £405
SSRIs (sertraline) Mean daily dosage 150mg, 4 GP visits at 0–3 months + 1 visit at 3–6 months, monitoring lab testing 0–3 months: £155
3–6 months: £39
If side effects: £37
For people experiencing side effects: 1 extra GP visit over 3 months, medication for management.
Combined TF-CBT/SSRIs Sum of the individual treatment components 0–3 months: £1,523 3–6
months: £39
Self-help with support Fixed cost of provider of digital programmes, hardware & capital overheads, 180 minutes of
support by a band 6 psychological therapist
£266
Self-help without support Fixed cost of provider of digital programmes, hardware & capital overheads, 40 minutes of support
by a band 6 psychological therapist
£98
Counselling 10 x 1 hr individual sessions (10 hours) delivered by a Band 7 psychological therapist £1,014
Psychoeducation 3 x 1 hr individual sessions (3 hours) delivered by a band 5 PWP £127
No treatment No resource use £0
EMDR: eye movement desensitisation reprocessing; IPT: interpersonal psychotherapy; PWP: psychological well-being practitioner; TF-CBT: trauma-focused cognitive
behavioural therapy
Unit cost of band 7 psychological therapists: £101 per hour of direct contact with the client–see S3 File for details on estimation of unit cost
Unit cost of band 5 PWPs: £42 per hour of direct contact with the client–see S3 File for details on estimation of unit cost
Unit cost of band 6 psychological therapist: £72 per hour of direct contact with the client (mean value of unit costs of band 7 psychological therapist and band 5 PWP)
Unit cost of GP: £37 per patient contact lasting 9.22 minutes [22]
Sertraline acquisition cost: 100mg, 28 tab, £0.99 [23]– 3-month cost £1.59
Cost of monitoring lab testing (SSRIs): £5 per person (expert advice)
Cost of medication for management of side effects (SSRIs): £3 per person over 3 months (expert advice)
Fixed cost of provider of digital programmes: £36.20 per person (expert advice)
Cost of hardware & capital overheads: £14 per person [24]
https://doi.org/10.1371/journal.pone.0232245.t001
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The mean ranking by cost-effectiveness is reported for each intervention (out of 10,000 iter-
ations), where a rank of 1 suggests that an intervention is the most cost-effective amongst all
evaluated treatment options. The probability of the intervention with the highest NMB being
the most cost-effective option is also provided, calculated as the proportion of iterations in
which the intervention has had the highest NMB amongst all interventions considered in the
analysis. The probability of cost-effectiveness has been estimated in a step-wise approach,
according to which the most cost-effective intervention is omitted at each step, and the proba-
bility of cost-effectiveness of the next most cost-effective intervention amongst the remaining
treatment options is re-calculated. The probabilities estimated following this approach reflect
the uncertainty around the cost-effectiveness not only of the most cost-effective intervention,
but also of the second, third, fourth, etc. most cost-effective intervention in ranking, after
more cost-effective interventions have been omitted from analysis. Finally, the cost-effective-
ness acceptability frontier has been plotted, showing the treatment with the highest mean
NMB over different cost-effectiveness thresholds (ĕ), and the probability that this treatment is
the most cost-effective among those assessed [33].
Table 2 reports the values of all model input parameters. Deterministic values were used in
deterministic one-way sensitivity analyses. The probability distributions show the types and
range of distributions assigned to each parameter; estimation of distribution ranges was based
on data reported in the published sources of evidence.
Two probabilistic analyses were undertaken, each using different assumptions on the effec-
tiveness of interventions at the 3-month follow-up:
• Base-case analysis: treatment effect between 3–6 months equalled that of no treatment
• Secondary analysis: treatment effect between 3–6 months equalled that estimated from the
NMA of changes in PTSD symptoms between baseline and 1-4-month follow-up
One-way deterministic sensitivity analyses explored the following scenarios applied onto
the base-case analysis:
• change in the annual risk of relapse between 0.05 and 0.20
• change in the PTSD health state cost by ± 50%
• use of alternative utility scores for the PTSD and no-PTSD states [19].
Validation of the economic model
The economic model was developed in collaboration with members of the guideline commit-
tee. All inputs and model formulae were systematically checked. The model was tested for logi-
cal consistency by setting input parameters to null and extreme values and examining whether
results changed in the expected direction. Results were discussed with the committee to con-
firm their plausibility.
Results
Table 3 shows the results of the base-case economic analysis. Interventions have been ordered
from the most to the least cost-effective. The table provides the mean number of QALYs, inter-
vention costs and total costs per person, the mean NMB and ranking of each intervention, and
its probability of being cost-effective in a step-wise approach at a threshold of £20,000/QALY.
EMDR was found to be the most cost-effective intervention for adults with PTSD, with the
highest NMB at the cost-effectiveness threshold of £20,000/QALY. This was followed by
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Table 2. Economic model input parameters.
Input parameter Deterministic
value
Probability distribution (type, range) Sources–comments
Characteristics of study population
Starting age of cohort
(years)
39 No distribution [6]; mean age of adults referred for assessment for possible PTSD in a UK NHS
outpatient clinic
Proportion of women 0.52 No distribution Calculated using the proportion of women in the general population aged 39
years [7], and data on the percentage of people screened positive for PTSD by
age and sex [4].
Odds ratios of remission versus no treatment at treatment endpoint
EMDR 42.18 95% CrI: 13.59 to 132.42 [3]; standardised mean differences converted to odds ratios according to [34];
distribution based on 300,000 samples from posterior distributions outputted
from NMAs, thinned by 30 to obtain 10,000 values
TF-CBT 14.06 95% CrI: 6.76 to 29.81
non-TF-CBT 9.09 95% CrI: 2.50 to 33.62
Combined somatic/
cognitive therapies
21.33 95% CrI: 3.84 to 121.63
SSRIs 7.99 95% CrI: 1.50 to 44.61
Combined TF-CBT/SSRIs 9.06 95% CrI: 1.15 to 69.34
Self-help with support 13.98 95% CrI: 2.74 to 70.74
Self-help without support 5.17 95% CrI: 1.29 to 20.27
Counselling 3.70 95% CrI: 1.12 to 12.38
Psychoeducation 8.99 95% CrI: 0.26 to 276.72
Odds ratios of remission versus no treatment at 3-month follow-up (secondary analysis only)
EMDR 7.53 95% CrI: 1.55 to 35.77 [3]; standardised mean differences converted to odds ratios according to [34];
distribution based on 300,000 samples from posterior distributions outputted
from NMAs, thinned by 30 to obtain 10,000 values
3-6-month probability of remission for SSRIs assumed to equal the probability
of remission of SSRIs during initial treatment (0–3 months); 3-6-month
probability of remission for combined TF-CBT/SSRIs borrowed from TF-CBT.
TF-CBT 3.80 95% CrI: 1.49 to 9.72
non-TF-CBT 2.18 95% CrI: 0.37 to 12.40
Combined somatic/
cognitive therapies
8.08 95% CrI: 0.41 to 155.56
SSRIs No data No data
Combined TF-CBT/SSRIs No data No data
Self-help with support 10.11 95% CrI: 2.03 to 48.96
Self-help without support 8.85 95% CrI: 0.73 to 105.43
Counselling 1.73 95% CrI: 0.37 to 8.15
Psychoeducation 2.58 95% CrI: 0.42 to 15.43
Probability of remission–no treatment (also applied to all interventions between 3–6 months in the base-case analysis & all interventions beyond 6 months in
the base-case and secondary analyses)
0–3 months from PTSD
onset
0.03 Beta: ċ = 17.26; Č = 646.74 [12]. See S2 File for details
0–12 months from PTSD
onset
0.15 Beta: ċ = 98.94; Č = 565.06
0–24 months from PTSD
onset
0.27 Beta: ċ = 176.62; Č = 487.38
0–36 months from PTSD
onset
0.32 Beta: ċ = 212.48; Č = 451.52
Risk of relapse–all treatments
3-month risk 0.026 Beta: ċ = 2.60; Č = 97.40 Expert opinion
Risk of developing common side effects from SSRIs
3-month risk 0.029 Beta: ċ = 687; Č = 22,933 [13]
Mortality
Hazard ratio–PTSD vs no
PTSD
1.77 Log-normal: 95% CI 1.02 to 3.14 [16]
Baseline mortality–
general population
Age/sex specific No distribution General mortality statistics for the UK population [17]
(Continued)
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Table 2. (Continued)
Input parameter Deterministic
value
Probability distribution (type, range) Sources–comments
Utility values
Base-case analysis
PTSD, men 0.54 Beta: ċ = 26.83; Č = 22.86 [18]; distribution estimated based on method of moments
PTSD, women 0.57 Beta: ċ = 86.75; Č = 65.44
No PTSD, men 0.63 Beta: ċ = 5.11; Č = 3.00
No PTSD, women 0.64 Beta: ċ = 14.11; Č = 7.93
Sensitivity analysis
PTSD, all 0.61 No distribution [19]
No PTSD, all 0.64
Disutility due to side effects from SSRIs
% reduction in health
state utility
10.3 Beta: ċ = 89.64; Č = 784.07 [21]; disutility applied as a percentage onto the health state (PTSD or no
PTSD) utility
Intervention costs–resource use
Number of sessions
EMDR 6 0.70: 5–6, 0.16: 4, 0.14: 3 Different probabilities assigned to different numbers of sessions for each
therapy, based on resource use reported in the RCTs included in the NMAs
that informed the economic analysis, supplemented by further assumptions.
Combined TF-CBT/SSRIs: resource use was the sum of the resource use of the
individual treatment components.
Details on intervention costs are provided in Table 1.
TF-CBT 9 0.70: 7–9, 0.16: 5–6, 0.14: 3–4
non-TF-CBT 9 0.70: 7–9, 0.16: 5–6, 0.14: 3–4
Combined somatic/
cognitive therapies
4 0.70: 4, 0.30: 2–3
Counselling 10 0.70: 8–10, 0.16: 5–7, 0.14: 3–4
Psychoeducation 3 0.70: 3, 0.16: 2, 0.14: 1
Therapist time (minutes)
Self-help with support 180 Normal: SD = 0.30�mean SD based on assumption
Self-help without support 40 Normal: SD = 0.30�mean
Number of GP contacts–SSRIs
0–3 months 4 0.70: 4, 0.30: 2–3 Different probabilities assigned to different numbers of sessions; number of
visits based on expert opinion; distribution based on assumption.3–6 months 1 0.70: 1, 0.30: 0
Treatment of side effects 1 0.80: 1, 0.20: 2
Intervention costs—unit
costs
SSRI– 3-month drug
acquisition
£1.59 No distribution [23]
Laboratory testing–SSRIs £5 No distribution Assumption
Medication for side
effects–SSRIs
£3 No distribution Assumption
Self-help infrastructure £50 No distribution Fixed digital therapy provider cost based on expert advice; capital cost based
on [24]
GP unit cost £37 Normal, SE = 0.05 of the mean [22]; distribution based on assumption
Band 7 clinical
psychologist unit cost
£101 Normal: SE = 0.05 of the mean See S3 File; distribution based on assumption
Band 5 PWP unit cost £42 Normal, SE = 0.05 of the mean See S3 File; distribution based on assumption
Band 6 therapist unit cost £72 Determined by distribution of Band 7
and Band 5 therapist unit costs
Assumed to be the mean of Band 7 and Band 5 therapist unit costs
3-month NHS/PSS health state cost
PTSD £293 Gamma: SE = 0.30 of the mean Based on resource use data reported in national and other published sources
[4, 27–29], supplemented with expert opinion and combined with national
unit costs [22, 23, 30], expressed in 2017 prices; see S4 File for details.
No-PTSD £27 Gamma: SE = 0.30 of the mean
(Continued)
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combined somatic/cognitive therapies, self-help with support, psychoeducation, SSRIs,
TF-CBT, self-help without support, non-TF-CBT, combined TF-CBT/SSRIs, no treatment and
counselling. The probability of EMDR being the most cost-effective treatment amongst the 11
options assessed was only 0.34. The probabilities of cost-effectiveness for next interventions in
ranking up to (and including) self-help without support did not exceed 0.42, although increas-
ingly fewer interventions were included in the analysis, indicating uncertainty in the results.
Notably, counselling was less cost-effective than no treatment; this finding was attributed to
the relatively low clinical effectiveness of counselling (the lowest amongst all active treatments
assessed in the economic analysis), which did not offset its relatively high intervention cost.
The cost-effectiveness plane (Fig 2) depicts the mean incremental costs and QALYs of all inter-
ventions versus no treatment (placed at the origin). According to the cost-effectiveness accept-
ability frontier (Fig 3), combined somatic/cognitive therapies appeared to be most cost-
effective amongst the 11 treatment options assessed for thresholds up to £2,500/QALY, with a
low probability that reached 0.25 at maximum, whereas EMDR became the most cost-effective
option at higher thresholds, with a probability that ranged from 0.19 to 0.41 amongst the 11
options assessed.
Results of the secondary analysis, which utilised 3-month NMA follow-up data, were not
very different. The top 3 interventions (EMDR, combined somatic/cognitive therapies, self-
Table 2. (Continued)
Input parameter Deterministic
value
Probability distribution (type, range) Sources–comments
Annual discount rate 0.035 No distribution Applied to costs and QALYs [31]
CI: confidence intervals; CrI: credible intervals; EMDR: eye movement desensitisation reprocessing; GP: general practitioner; IPT: interpersonal psychotherapy; NHS:
National Health Service; PSS: personal social services; PTSD: post-traumatic stress disorder; PWP: psychological well-being practitioner; SD: standard deviation; SE:
standard error; SSRI: selective serotonin reuptake inhibitor; TF-CBT: trauma-focused cognitive behavioural therapy
https://doi.org/10.1371/journal.pone.0232245.t002
Table 3. Base-case results of economic modelling.
Intervention Mean per person NMB (£/ person) Mean rank Prob�
QALY Intervention cost (£) Total cost (£) (at a threshold of £20,000/
QALY)
EMDR 1.80 746 2,047 33,928 2.31 0.34
Combined somatic/cognitive therapies 1.77 360 1,963 33,364 3.28 0.35
Self-help with support 1.75 266 2,047 32,880 4.01 0.32
Psychoeducation 1.74 108 1,982 32,754 4.90 0.42
SSRIs 1.72 146 2,143 32,316 5.15 0.37
TF-CBT 1.74 1,058 2,854 32,042 6.38 0.26
Self-help without support 1.71 98 2,253 31,865 6.19 0.41
non-TF-CBT 1.73 705 2,670 31,860 6.79 0.50
Combined TF-CBT/SSRIs 1.73 1,204 3,140 31,451 8.19 0.48
No treatment 1.67 0 2,488 30,915 9.14 0.64
Counselling 1.69 785 3,043 30,854 9.66 1.00
EMDR: eye movement desensitisation reprocessing; NMB: net monetary benefit; Prob: probability of cost-effectiveness; SSRIs: selective serotonin reuptake inhibitors;
TF-CBT: trauma-focused cognitive behavioural therapy
�estimated in a step-wise approach, according to which the most cost-effective intervention is omitted at each step, and the probability of cost-effectiveness of the next
most cost-effective intervention amongst the remaining treatment options is re-calculated
https://doi.org/10.1371/journal.pone.0232245.t003
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help with support) remained the same. The ranking of self-help without support improved
and counselling became better than no treatment. The probabilities of cost-effectiveness of the
top 5 interventions were low, ranging between 0.14 and 0.47, indicating uncertainty around
the results. Self-help without support appeared to be the most cost-effective option at a zero
cost-effectiveness threshold and combined somatic/cognitive therapies were most cost-effec-
tive at higher thresholds up to £18,000/QALY; EMDR was the most cost-effective option at
higher thresholds, with a 0.14 probability at the threshold of £20,000/QALY. Results of the
secondary analysis are provided in S5 File.
In deterministic sensitivity analyses, results were, overall, robust to changes in the risk of
relapse and in the PTSD health state cost and rankings were not affected. TF-CBT was the only
option that dropped (by one place) in ranking when the baseline risk of relapse was increased
by 50% or the PTSD health state cost was reduced by 50%. Use of alternative utility data that
assumed narrower HRQoL benefits associated with remission had a small impact on the
results, with the relative cost-effectiveness of TF-CBT alone or combined with SSRIs and non-
Fig 2. Cost-effectiveness plane: Base-case analysis results for 1,000 adults with PTSD.
https://doi.org/10.1371/journal.pone.0232245.g002
Fig 3. Cost-effectiveness acceptability frontier: Base-case analysis.
https://doi.org/10.1371/journal.pone.0232245.g003
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TF-CBT being reduced. However, results for other interventions were not affected. Results of
deterministic sensitivity analyses are shown in S6 File. For information, results of the NICE
guideline economic analysis are shown in S7 File.
Discussion
Overview of findings
EMDR appears to be the most cost-effective intervention for adults with PTSD more than 3
months after trauma, followed by combined somatic/cognitive therapies, self-help with sup-
port, psychoeducation, SSRIs, TF-CBT, self-help without support, non-TF-CBT and combined
TF-CBT/SSRIs. Counselling appears to be less cost-effective than no treatment, due to its rela-
tively low clinical effectiveness (the lowest amongst all active treatments assessed in the eco-
nomic analysis), as shown in the NMAs that informed the economic analysis [3], which was
not enough to offset its relatively high intervention cost. The low effectiveness found for coun-
selling can be attributed to counselling’s non-directive person-centred approach, which is less
likely to help the person overcome avoidance (which is one of the criteria for PTSD), and thus
less likely to reduce PTSD symptoms. On the other hand, counselling’s effectiveness may have
been underestimated to some extent due to researcher allegiance, since in the vast majority of
the RCTs on counselling that informed the economic analysis, counselling served as a control
treatment to other active interventions, primarily TF-CBT [3].
Results were characterised by uncertainty, as reflected in relatively low probabilities of each
intervention being cost-effective amongst alternative treatment options; however they were
overall robust to assumptions tested through deterministic sensitivity analyses.
Strengths and limitations
Our analysis utilised effectiveness data derived from a systematic review and NMA of changes
in PTSD symptoms [3]. This methodology enabled us to consider information from direct and
indirect comparisons between interventions, and allowed simultaneous comparisons across all
options while preserving randomisation [35]. This approach for evidence synthesis is essential
for populating model-based economic studies assessing more than two competing interven-
tions. No inconsistency was detected between direct and indirect evidence. We used 10,000
iterations of the NMAmodels in the economic analysis, which represent the full uncertainty
and correlation in the relative effects.
The NMA that informed the base-case economic analysis (changes in PTSD symptoms
between baseline and treatment endpoint) used a large evidence base and produced robust
data. The NMA of 1-4-month follow-up changes in PTSD symptoms, which informed the
secondary analysis, showed considerable uncertainty for most interventions, due to the small
number and size of the included studies; TF-CBT and EMDR were the only treatments in this
NMA with data on at least 100 people at 1-4-month follow-up that showed evidence of sus-
tained effect. Thus, results of this secondary economic analysis should be interpreted with
caution. Both NMAs were characterised by high between-trial heterogeneity, which is likely to
have been caused by heterogeneity across populations included in the trials considered in the
NMAs, for example, in terms of the presence of a formal PTSD diagnosis, the severity, com-
plexity and chronicity of PTSD symptoms, the type, extent and multiplicity of trauma expo-
sure, the presence of comorbidity, and also the variability of interventions within each assessed
option and the differences across settings, e.g. inpatient versus outpatient delivery of interven-
tions [3]. Heterogeneity may also have been caused by the type, multiplicity and timing of pre-
vious treatments in trial participants, but relevant information was not available in the
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majority of the RCTs included in the NMAs; therefore, the impact of previous treatments on
the effectiveness of the interventions cannot be assessed.
Regarding the potential heterogeneity across populations in the trials that informed the eco-
nomic model, it should be noted that, of the 82 studies that were included in the NMAs that
informed the economic analysis, 50 (61%) recruited people with a formal PTSD diagnosis
whereas the remaining 32 (39%) recruited people with clinically important PTSD symptoms, as
indicated by baseline scores above a predefined threshold on a validated PTSD symptom scale.
The percentage of trials recruiting people with a formal PTSD diagnosis was relatively high
(range 70–100%) among trials assessing TF-CBT alone or combined with SSRIs, EMDR and
counselling; moderate (range 50–66%) among trials assessing non-TF-CBT and self-help with
support; and rather low (range 25–33%) among trials assessing combined somatic/cognitive
therapies, self-help without support and psychoeducation ([3]; see S5 Appendix for population
characteristics of included studies in the NMA). It may be hypothesised that a formal diagnosis
of PTSD is associated with more severe symptoms at baseline, resulting in interventions tested
on such populations appearing to be less clinically and cost-effective compared with interven-
tions tested on people with clinically important PTSD symptoms, who may have had less severe
symptoms at baseline. Nevertheless, the NMA and economic modelling results did not confirm
such a hypothesis, since, for example, EMDR and, to a lesser degree, TF-CTB, showed high
clinical and cost-effectiveness, despite both having been tested in RCTs that, in their majority,
recruited people with a formal PTSD diagnosis. On the other hand, it is possible that partici-
pants in the trials that recruited people with clinically important PTSD symptoms might meet
criteria for (and might have received) a formal PTSD diagnosis, but they were not required to
do so in order to participate in the trial, and this could well have been for pragmatic reasons
related to trial management rather than an intention to recruit people with potentially lower
symptom severity. Furthermore, for PTSD symptom scales that are based closely on diagnostic
criteria, e.g. PTSD Checklist (PCL), scoring above the clinical threshold may be regarded as
comparable to receiving a formal diagnosis of PTSD. Related to this point, we should note that
all RCTs that evaluated combined somatic/cognitive therapies and recruited people with clini-
cally important PTSD symptoms used scales that are based on diagnostic criteria (e.g. PCL and
Modified PTSD Symptom Scale [MPSS-SR]); similarly, the majority of the studies that evalu-
ated psychoeducation and recruited people with clinically important PTSD symptoms used
scales based on diagnostic criteria (e.g. PCL and Davidson Trauma Scale). Consequently, the
symptom severity of trial populations receiving combined somatic/cognitive therapies and psy-
choeducation (who, in the majority of trials, were not required to have a formal diagnosis of
PTSD) was likely similar to the symptom severity of populations with a formal diagnosis of
PTSD receiving other interventions considered in our NMA and economic analysis.
The strengths and limitations of the NMAs that informed the economic analyses should be
considered when interpreting the cost-effectiveness results. Moreover, the quality and limita-
tions of RCTs considered in the NMAs have unavoidably impacted on the quality of the model
input parameters. Although all interventions included in the economic analysis had been
tested on at least 100 trial participants for treatment endpoint, the size of the evidence base
differed considerably across interventions. TF-CBT had by far the largest evidence base in
both NMAs (N = 903 across 29 RCTs at treatment endpoint and N = 753 across 13 RCTs at 1-
4-month follow-up), which gives us more confidence in the results on its clinical (and, conse-
quently, cost-) effectiveness. The evidence base was more limited for other interventions
included in the economic analysis (each tested on N<350 in each of the two NMAs). For
comparison, EMDR, which was shown to be the most cost-effective treatment option in our
economic analysis, was tested on N = 260 across 11 RCTs at treatment endpoint and N = 121
across 4 RCTs at 1-4-month follow-up in the NMAs that informed the economic analysis [3].
PLOS ONE Cost-effectiveness of psychological treatments for PTSD in adults
PLOS ONE | https://doi.org/10.1371/journal.pone.0232245 April 30, 2020 15 / 22
The economic model structure did not incorporate discontinuation due to limited data avail-
ability. However, the NMAs that informed the economic analysis utilised intention-to-treat data,
where available, so that discontinuation has been implicitly considered in the economic analysis.
The probabilistic analysis took into account, where possible, the completion rates of the interven-
tions in the RCTs that informed the economic analysis, so that the number of sessions reflected,
up to a degree, the attrition rates of each intervention. The time horizon of the analysis was 3
years, in order to capture longer-term effects and costs associated with a course of treatment for
PTSD without significant extrapolation over the natural course of PTSD.
The baseline risk of remission was estimated from a large longitudinal study on adults with
PTSD in the community [12], as the survey’s target population was deemed to be directly rele-
vant to our study population. The risk of relapse was not available in published literature, and
was therefore based on expert opinion. Utility data were derived from a systematic literature
review. Costs incurred by adults with PTSD and those remitting from PTSD were based on
published national survey data, supplemented with other published evidence and expert opin-
ion, due to lack of more accurate information. Sensitivity analysis showed that results were
robust to use of alternative values for the risk of relapse, utility and costs. The risk of side
effects from SSRIs was based on an uncontrolled study that did not examine the rate of side
effects that were attributable to SSRIs. Therefore, our economic analysis may have overesti-
mated the impact of common side effects from SSRIs relative to other treatments and thus
may have underestimated the relative cost effectiveness of SSRIs.
In conclusion, our study is characterised by different strengths and limitations, which we
have considered when constructing our model and interpreting the results of our analysis. We
carried out probabilistic analyses, which took into account the uncertainty around model
parameters and, where possible, we conducted secondary and deterministic sensitivity analyses
to address uncertainties and gaps in the evidence.
Comparison with existing economic evidence
Published economic evaluations of interventions for PTSD in adults have concluded that expo-
sure therapy (a form of TF-CBT) is more cost-effective than no treatment [36]. TF-CBT and
SSRIs are likely more cost-effective than usual care [18]; prolonged exposure (TF-CBT) has
been found to be more cost-effective than SSRIs [37]. Finally, self-management was shown to
be no more effective but overall less costly than psychoeducation [38]. These economic studies
evaluated a limited range of interventions for adults with PTSD and made very few compari-
sons between active interventions; notably, EMDR, which was shown to be the most cost-effec-
tive intervention in our analysis, has not been evaluated in previously published economic
literature on adults with PTSD.
Overall, our findings are in agreement with previously published evidence. Our economic
analysis estimated the cost-effectiveness of a wider range of interventions available for adults
with PTSD, such as EMDR, combined somatic/cognitive therapies, self-help, non-TF-CBT
and counselling and allowed, for the first time, simultaneous comparisons of cost-effectiveness
across interventions, and their ranking from the most to the least cost-effective.
On the other hand, an economic evaluation of psychological interventions for PTSD in chil-
dren and young people, which also used efficacy data derived from a NMA and adopted a sim-
ilar approach and methodology to the analysis described here, concluded that individual forms
of TF-CBT were most cost-effective in the treatment of children and young people with PTSD,
whereas EMDR occupied middle cost-effectiveness rankings amongst the treatment options
assessed [39]. This finding was attributed to the lower effectiveness of EMDR relative to other
treatments in children and young people compared with adult populations [40].
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Generalisability of the results and implications of the study
Our analysis was conducted from the perspective of the NHS/PSS in England. Results may be
generalisable to other settings with similar funding and structure of healthcare and personal social
services and comparable care pathways for adults with PTSD. Conclusions on cost-effectiveness
ultimately rely on the cost-effectiveness threshold adopted, and this depends on the policy makers’
willingness-to-pay for treatment benefits, which may vary across countries and health systems.
Our analysis estimated the resource use relating to the delivery of each intervention based
on information reported in the RCTs that informed the economic analysis; for example, the
mode number of hours for a course of EMDR and TF-CBT was 9 and 13.5, respectively. If the
duration and therefore the cost of an intervention is considerably different from our estimates,
then its relative cost-effectiveness is expected to be affected. However, reducing the number of
sessions of an intervention will improve its cost-effectiveness only if its clinical effectiveness
remains unaffected. In practice, a reduction in the number of sessions below a point that is
critical for the optimal delivery of the intervention is expected to reduce its clinical effective-
ness, too; the impact on its cost-effectiveness will depend on the trade-off between a lower
intervention cost and a lower clinical effectiveness.
Based on the results of the NMAs and the economic analysis, the NICE guideline on PTSD
recommended EMDR and individual TF-CBT for the treatment of adults with PTSD presenting
more than 3 months after trauma [5]. Both interventions were shown to be effective in reducing
PTSD symptoms post-treatment and were the only ones with sufficient evidence to suggest sus-
tainment of effect beyond treatment. EMDR appeared to be the most cost-effective intervention
amongst those assessed. TF-CBT appeared to be less cost-effective than other interventions (i.e.
combined somatic/cognitive therapies, psychoeducation, self-help with support and SSRIs), but
had by far the largest evidence base and the guideline economic analysis showed that brief indi-
vidual TF-CBT (delivered in fewer than 8 sessions) had the highest clinical and cost effectiveness
amongst all options assessed; the finding that brief individual TF-CBT had the highest clinical
effectiveness was explained by inspection of the clinical data, which revealed that participants in
trials of brief individual TF-CBT had less severe PTSD symptoms at baseline, and therefore were
likely to have a better response to treatment, compared with participants in trials of more inten-
sive forms of individual TF-CBT. The recommendation for EMDR was restricted to people with
non-combat-related trauma, as evidence suggested a non-significant effect on people with com-
bat-related trauma.
The NICE guideline recommendations on TF-CBT and EMDR for adults with PTSD are
consistent with other published PTSD clinical practice guidelines (compared in [41]). Three
more guidelines make recommendations of equal strength for TF-CBT and EMDR [42–44],
whereas one guideline makes a strong recommendation for TF-CBT while EMDR has been
given a moderate rating [45].
Self-help with support was shown to be the third most cost-effective option amongst those
assessed, owing to a combination of its high effectiveness at treatment endpoint (informed by
N = 198 across 5 RCTs in the respective NMA [3]) and its low intervention cost. There was
also limited evidence (N = 85 across 3 RCTs in the respective NMA [3]) that it can sustain
effects beyond treatment endpoint. All 5 RCTs on self-help with support that informed the
economic analysis focused on computerised TF-CBT, which is consistent with TF-CBT deliv-
ered by a therapist, and this element may have been the driver of the intervention’s clinical
effectiveness. The NICE guideline committee considered the clinical and cost-effectiveness of
self-help with support and, also, that of SSRIs, but noted their narrower evidence base and
made weaker (‘consider’) recommendations for people who expressed a preference for these
interventions, and, in the case of self-help, did not have severe PTSD symptoms and were not
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at risk of harm to themselves or others. Based on its middle rankings in the NMA and eco-
nomic analysis, a ‘consider’ recommendation was also made for non-TF-CBT targeted at
specific symptoms, for people who are unable or unwilling to engage in a trauma-focused
intervention or have residual symptoms after treatment. Psychoeducation was shown to be
cost-effective based on limited and inconclusive clinical evidence; therefore, it was not recom-
mended as a stand-alone intervention, but as part of individual TF-CBT. Finally, the commit-
tee noted the evidence of high clinical and cost-effectiveness for combined somatic/cognitive
therapies, but also considered their particularly limited evidence base beyond treatment end-
point and the lack of specific indications for these interventions, and decided not to recom-
mend them but instead to make a recommendation for further research [5].
Conclusion
EMDR appears to be the most cost-effective intervention for adults with PTSD more than 3
months after trauma, followed by combined somatic/cognitive therapies, self-help with sup-
port, psychoeducation, SSRIs, TF-CBT, self-help without support, non-TF-CBT and combined
TF-CBT/SSRIs. Counselling appears to be less cost-effective than no treatment. Results were
characterised by uncertainty, and relatively limited evidence base for interventions other than
TF-CBT. There is a need for well-conducted studies that examine the relative clinical and cost-
effectiveness of a range of psychological treatments for adults with PTSD, in particular assess-
ment of longer-term costs and effects, to reduce the uncertainty and limitations characterising
current evidence.
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